Form 8-K - Current report:
SEC Accession No. 0001104659-25-030839
Filing Date
2025-04-02
Accepted
2025-04-02 06:06:33
Documents
16
Period of Report
2025-04-02
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2510984d2_8k.htm   iXBRL 8-K 43544
2 EXHIBIT 99.1 tm2510984d2_ex99-1.htm EX-99.1 24086
6 GRAPHIC tm2510984d2_ex99-1img001.jpg GRAPHIC 34776
7 GRAPHIC tm2510984d2_ex99-1img002.jpg GRAPHIC 132069
  Complete submission text file 0001104659-25-030839.txt   482435

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ewtx-20250402.xsd EX-101.SCH 3020
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ewtx-20250402_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ewtx-20250402_pre.xml EX-101.PRE 22362
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2510984d2_8k_htm.xml XML 3567
Mailing Address 1715 38TH ST BOULDER CO 80301
Business Address 1715 38TH ST BOULDER CO 80301 720-262-7002
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40236 | Film No.: 25801904
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)